Skip to content
value.today

Agile Therapeutics Inc.

Total raised
$90 M
7 rounds on record
Latest round
$8 M
Mar 2019
First round on record
Oct 2009
Today
Private
No later event on record

Funding rounds

7 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Agile Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2019$8 MNo. 7$2 to $10 million

Agile Therapeutics Inc.: Raise no. 7, Mar 2019

Investors in this round

1 investor had bought by the notice of Mar 14, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Agile Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Al Altomari · Executive Officer, Director
  • Elizabeth M. Garner · Executive Officer
  • Geoffrey P. Gilmore · Executive Officer
  • Robert G. Conway · Executive Officer
  • Scott M. Coiante · Executive Officer
  • Abhijeet P. Lele · Director
  • Ajit S. Shetty · Director
  • James P. Tursi · Director
  • John S. Hubbard · Director
  • Seth H.Z. Fischer · Director
  • William T. McKee · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Al Altomari, Chief Executive Officer. Newest notice filed Mar 14, 2019. Read the notice at the SEC.

equitySEC
Jan 2015$20 MNo. 6$10 to $50 million

Agile Therapeutics Inc.: Raise no. 6, Jan 2015

Investors in this round

8 investors had bought by the notice of Feb 6, 2015: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Agile Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$20 M of $20 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$600,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Al Altomari · Executive Officer, Director
  • Elizabeth M. Garner · Executive Officer
  • Katie M. MacFarlane · Executive Officer
  • Scott M. Coiante · Executive Officer
  • Abhijeet M. Lele · Director
  • Andrew N. Schiff · Director
  • James N. Tursi · Director
  • John T. Hubbard · Director
  • Karen M. Hong · Director
  • William T. McKee · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • William Blair & Company, L.L.C. (CRD 1252) · Chicago, IllinoisSold in MA, NJ

Signed by Al Altomari, Chief Executive Officer. Newest notice filed Feb 6, 2015. Read the notice at the SEC.

equitySEC
Apr 2014$3 MNo. 5$2 to $10 million

Agile Therapeutics Inc.: Raise no. 5, Apr 2014

Investors in this round

9 investors had bought by the notice of May 9, 2014: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Agile Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$300,000 (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Al Altomari · Executive Officer, Director
  • Elizabeth M. Garner · Executive Officer
  • Katie M. MacFarlane · Executive Officer
  • Scott M. Coiante · Executive Officer
  • Abhijeet M. Lele · Director
  • Andrew N. Schiff · Director
  • Karen M. Hong · Director
  • Lorenzo N. Pellegrini · Director
  • William T. McKee · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Al Altomari, Chief Executive Officer. Newest notice filed May 9, 2014. Read the notice at the SEC.

debt, optionsSEC
Jul 2012$24 MNo. 4$10 to $50 million

Agile Therapeutics Inc.: Raise no. 4, Jul 2012

Investors in this round

13 investors had bought by the notice of Jul 31, 2012: 13 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Agile Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$24 M of $41 M offered; $17 M still to sell
Smallest investment taken
$831
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
$350,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Al Altomari · Executive Officer, Director
  • Scott Coiante · Executive Officer
  • Abhijeet LeLe · Director
  • Andrew Schiff · Director
  • Karen Hong · Director
  • Lorenzo Pellegrini · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes cash proceeds and proceeds of indebtedness of the Issuer converted in the offering”

Signed by Al Altomari, President. Newest notice filed Jul 31, 2012. Read the notice at the SEC.

equitySEC
May 2010$33 MNo. 3$10 to $50 million

Agile Therapeutics Inc.: Raise no. 3, May 2010

Investors in this round

14 investors had bought by the notice of Jul 11, 2011: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Agile Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$33 M of $45 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$1,600,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Al Altomari · Executive Officer, Director
  • Scott Coiante · Executive Officer
  • Abhijeet Lele · Director
  • Karen Hong · Director
  • Lorenzo Pellegrini · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Al Altomari, President and Chief Executive Officer. Newest notice filed Jul 11, 2011 (1 amendment). Read the notice at the SEC.

equitySEC
Dec 2009$1 MNo. 2Under $2 million

Agile Therapeutics Inc.: Raise no. 2, Dec 2009

Investors in this round

14 investors had bought by the notice of Jan 12, 2010: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Agile Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $2 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
$90,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Thomas M. Rossi · Executive Officer, Director
  • Al M. Altomari · Director
  • Dean M. Miller · Director
  • Joyce M. Tsang · Director
  • Karen M. Hong · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Offering amount does not include exercise price for warrants issued in financing ($1,800,055.20) or principal and interest under notes converted into shares ($1,028,088.43).”

Signed by Thomas M. Rossi, President and Chief Executive Officer. Newest notice filed Jan 12, 2010. Read the notice at the SEC.

equity, optionsSEC
Oct 2009$1 MNo. 1Under $2 million

Agile Therapeutics Inc.: Raise no. 1, Oct 2009

Investors in this round

11 investors had bought by the notice of Oct 28, 2009: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Agile Therapeutics Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Thomas M. Rossi · Executive Officer, Director
  • Al M. Altomari · Director
  • Daria O. Blackwell · Director
  • Devang V. Kantesaria · Director
  • Karen O. Hong · Director
  • Paul J. Schmitt · Director
  • Russell W. Ayres · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Thomas M. Rossi, President and Chief Executive Officer. Newest notice filed Oct 28, 2009. Read the notice at the SEC.

equity, debt, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Agile Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2019).

    SEC Form D · Mar 2019

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2019

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in Agile Therapeutics Inc.
InvestorKindAmountRoundRoleSource
Care Capital III LLCFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Care Capital Investments III L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Care Capital Offshore Investments III LPFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
Investor ABFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
ProQuest Associates III LLCOthernot statednot statedHeld Series A-1, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
ProQuest Associates IV LLCOthernot statednot statedHeld Series A-1, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
ProQuest Investments III, L.P.Fund or asset managernot statednot statedHeld Series A-1, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3
ProQuest Investments IV, L.P.Fund or asset managernot statednot statedHeld Series A-1, B and C preferred stock, 10% owner (Form 3, 2014)SEC Form 3

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Agile Therapeutics Inc.
NameRoleNamed in
Al AltomariExecutive officerMar 2019
Elizabeth M. GarnerExecutive officerMar 2019
Geoffrey P. GilmoreExecutive officerMar 2019
Robert G. ConwayExecutive officerMar 2019
Scott M. CoianteExecutive officerMar 2019
Katie M. MacFarlaneExecutive officerFeb 2015
Scott CoianteExecutive officerJul 2012
Thomas M. RossiExecutive officerJun 2010
Abhijeet P. LeleDirectorMar 2019
Ajit S. ShettyDirectorMar 2019
Al AltomariDirectorMar 2019
James P. TursiDirectorMar 2019
John S. HubbardDirectorMar 2019
Seth H.Z. FischerDirectorMar 2019
William T. McKeeDirectorMar 2019
Abhijeet M. LeleDirectorFeb 2015
Andrew N. SchiffDirectorFeb 2015
James N. TursiDirectorFeb 2015
John T. HubbardDirectorFeb 2015
Karen M. HongDirectorFeb 2015
Lorenzo N. PellegriniDirectorMay 2014
Abhijeet LeLeDirectorJul 2012
Andrew SchiffDirectorJul 2012
Karen HongDirectorJul 2012
Lorenzo PellegriniDirectorJul 2012
Abhijeet LeleDirectorJul 2011
Al M. AltomariDirectorJun 2010
Lorenzo M. PellegriniDirectorJun 2010
Thomas M. RossiDirectorJun 2010
Dean M. MillerDirectorJan 2010
Joyce M. TsangDirectorJan 2010
Daria O. BlackwellDirectorOct 2009
Devang V. KantesariaDirectorOct 2009
Karen O. HongDirectorOct 2009
Paul J. SchmittDirectorOct 2009
Russell W. AyresDirectorOct 2009